

Patients on Warfarin Undergoing PCI: Construct for TRI Trials

Ian C Gilchrist, MD, FSCAI
Professor of Medicine
Penn State University
Heart & Vascular Institute
Hershey, PA

Warfarin Contraindication


TABLE 1.2. *Relative contraindications to cardiac catheterization and angiography*

- 1. Uncontrolled ventricular irritability: the risk of ventricular tachycardia/fibrillation during catheterization is increased if ventricular irritability is uncontrolled**
- 2. Uncorrected hypokalemia or digitalis toxicity**
- 3. Uncorrected hypertension: predisposes to myocardial ischemia and/or heart failure during angiography**
- 6. Anticoagulated state: Prothrombin time longer than 18 seconds**
- 4. Intercurrent febrile illness**
- 5. Decompensated heart failure: especially acute pulmonary edema, unless catheterization can be done with the patient sitting up**
- 6. Anticoagulated state: prothrombin time longer than 18 seconds**
- 7. Severe allergy to radiographic contrast agent**
- 8. Severe renal insufficiency and/or anuria: unless dialysis is planned to remove fluid and radiographic contrast load**

Expanding Population

- Atrial fibrillation
- Veno-embolic Disease
- Mechanical valves
- Cardiomyopathy


Expanding need for oral anticoagulation



Increased awareness by patients

Warfarin: *Stop, Bridge or Continue*


EP study of Device Implantation (N=459)



Heparin or Warfarin

(are they the same for transradial)

Association of heparin 50 U/kg or warfarin INR>2.0 with early/late radial artery occlusion after transradial cardiac catheterization.



Ahmed et al. *Catheter Cardiovasc Intervent* 2012;79;SCAI 2012 abstract, S103

Warfarin & IV Anticoagulation

	Warfarin	
	Interrupted INR<2 (N=44)	Continued INR>2 (N=73)
IV Heparin Added	90%	30%
Time to Hemostasis	177±77 minutes	154±82 minutes
Radial Occlusion	4%	20%

No differences in hematoma formation or procedural outcome

Tizon-Marcos, et al. Poster ESC 2009

Trials?

Registry (NCDR): Signals

- Short term events, only
- Mechanism to also track newer oral anticoagulants

Mechanistic Trial: Radial Occlusion

- Coumadin +/- heparin/LMWH/Xa Inhibitor/bivalirudin
- Should IV anticoagulant be dose-adjusted for INR?

Outcomes Trial: Thrombotic/Bleeding Events

- On a back ground of optimal antiplatelet therapy, does a dosing regimen have an advantage?

Discussion

